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PEMBANGUNAN DAN PENILAIAN SISTEM NASBA UNTUK DIAGNOSIS 
PENYAKIT TAUN MENGGUNAKAN KAEDAH ELISA DAN BIOSENSOR 
 
ABSTRAK 
 
Taun (kolera) ialah penyakit ciri-birit yang disebabkan Vibrio cholerae. Taun boleh 
membawa maut jika tidak dikesan dengan serta-merta. Justeru, pengesanan awal adalah 
penting untuk rawatan pesakit dan kawalan wabak taun. Ujian kultur dan biokimia 
konvensional adalah rumit, lambat dan kurang sensitif. Walaupun ujian berasaskan teknik 
molekul adalah lebih pantas, sensitif dan spesifik, kaedah ini memerlukan peralatan mahal 
dan penyimpanan sejuk bahan-bahan reagen. Ujian DNA seperti PCR tidak dapat 
membezakan sel hidup dengan sel mati. Kaedah amplifikasi berasaskan asid nukleik 
(NASBA) yang menggandakan RNA secara isoterma dapat mengesan sel hidup sahaja. 
Maka, objektif kajian ini adalah untuk membangunkan dan menilai suatu ujian NASBA-
ELISA yang stabil haba dengan biosensor untuk mengesan V. cholerae berasaskan gen lolB. 
Pada peringkat permulaan, transkrip RNA sebagai kawalan positif dikonstruk dan primer 
serta prob khusus direka. Pengoptimuman ujian NASBA dan ELISA dilakukan dan 
spesifisiti analitikal diuji dengan 41 bakteria rujukan yang terdiri daripada V. cholerae, 
Vibrio spesis dan patogen enterik. Sensitiviti analitikal diuji dengan cairan bersiri transkrip 
RNA dan sel-sel V. cholerae. Penilaian klinikal dijalankan dengan menggunakan najis yang 
ditokok sampel (n=200). Seterusnya, kaedah biosensor dioptimumkan dan keputusannya 
dibandingkan dengan kaedah spektrofotometri. Campuran NASBA dijadikan stabil haba 
melalui pengeringbekuan dan kestabilannya dinilai pada suhu berlainan untuk jangkamasa 
tertentu. Selain itu, kesesuaian lolB mRNA sebagai penunjuk kebolehhidupan diselidiki 
dengan membunuh sel-sel V. cholerae melalui pelbagai kaedah dan mengesan isyarat 
NASBA daripadanya. Ujian kolera NASBA-ELISA yang telah dioptimumkan berdasarkan 
pengesanan produk amplifikasi melalui prob berlabel fluorescein dan isyarat TMB/HRP. 
Spesifisiti analitikal ujian adalah 100% manakala sensitiviti analitikal ujian adalah 102 
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molekul/µl transkrip RNA dan 10 CFU/ml sel. Penilaian klinikal memberikan keputusan 
100% sensitif, 84.52% spesifik, 89.92% nilai ramalan positif dan 100% nilai ramalan negatif. 
Kaedah biosensor didapati setanding kaedah spektrofotometri dengan mencatatkan kepekaan 
analitikal yang sama, korelasi yang rapat (R2<0.964) dan persetujuan kappa yang hampir 
sempurna (95.1%, k = 0.828). Penstabilan campuran NASBA mampu mengekalkan 
kestabilannya pada 8°C dan -20°C selama dua bulan. Dalam ujian kebolehhidupan sel, gen 
lolB masih dapat dikesan daripada kultur sel V. cholerae yang telah dibunuh selepas 48 jam, 
justeru gen ini tidak sesuai dijadikan penunjuk sel bernyawa. Kesimpulannya, buat pertama 
kalinya, kami telah membangunkan suatu ujian kolera-NASBA-ELISA dengan pengesanan 
biosensor yang sensitif dan dapat dilakukan dengan peralatan mudah dalam empat jam. 
Campuran NASBA kering mengurangkan langkah-langkah mempipet serta memudahkan 
penghantaran dan penyimpanan ujian. Ujian ini sesuai sebagai ujian diagnostik pantas dan 
ujian saringan di lapangan.                  
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DEVELOPMENT AND EVALUATION OF A NASBA SYSTEM FOR THE 
DIAGNOSIS OF CHOLERA USING ELISA AND BIOSENSOR METHODS 
 
ABSTRACT 
 
Cholera is a diarrheal disease caused by Vibrio cholerae. Cholera is potentially 
lethal if not diagnosed on time. Hence, early detection is crucial for patient treatment and 
containment of outbreak. Conventional culture and biochemical tests are laborious, time-
consuming and less sensitive. Although molecular-based methods are rapid, more 
sensitive and specific; they require expensive equipments and cold storage of reagents. 
Furthermore, DNA-based tests such as PCR, do not distinguish between viable and non-
viable cells. Nucleic acid sequence-based amplification (NASBA) is an isothermal RNA 
amplification technique that specifically detects viable cells. Hence, the objective of this 
study was to develop and evaluate a thermostabilized cholera-NASBA-ELISA assay with 
biosensor detection for V. cholerae based on the lolB gene. RNA transcripts as positive 
control were first constructed and specific primers and probes were designed. NASBA and 
ELISA conditions were optimized and the analytical specificity was tested with 41 
reference strains comprising of V. cholerae, Vibrio species and enteric pathogens. The 
analytical sensitivity was tested with serial dilutions of RNA transcripts and V. cholerae 
cells. Clinical evaluation of the assay was performed using spiked stool samples (n=200). 
Subsequently, biosensor detection for the NASBA-ELISA assay was optimized and the 
results compared to spectrophotometry. The NASBA mix was thermostabilized by freeze-
drying and its stability at different temperatures was determined periodically. In addition, 
suitability of lolB mRNA as a viability indicator was investigated by subjecting cultures to 
lethal treatments and detecting the NASBA signal. The optimized cholera-NASBA-
ELISA assay detected amplicons using fluorescein-labeled probes and TMB/HRP signal. 
The analytical specificity of the assay was 100%, while the analytical sensitivity was 102 
molecules/µl RNA transcripts and 10 CFU/ml cells. Clinical evaluation gave 100% 
 xx 
sensitivity, 84.52% specificity, 89.92% PPV and 100% NPV. Biosensor detection was 
comparable to spectrophotometry, yielding similar analytical sensitivity level, excellent 
correlation (R2 <0.964) and near perfect kappa agreement (95.1%, k= 0.828). 
Thermostabilization of the NASBA mix was able to preserve its stability at 8°C and -20°C 
for two months. In the viability assay, lolB mRNA was detected even after 48 hours post-
treatment, therefore precluding its use as a viability indicator. In conclusion, we have for 
the first time, developed a sensitive cholera-NASBA-ELISA assay with biosensor 
detection that can be performed using simple equipments within four hours. The dry 
NASBA mix reduces multiple pipetting steps and facilitates transportation and storage. 
The test is suitable for use as a rapid diagnostic test or screening test in the field.     
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CHAPTER 1 
INTRODUCTION 
 
1.1 History of cholera 
Cholera is a potentially life-threatening secretory diarrheal disease caused by the 
bacteria Vibrio cholerae. Cholera is thought to originate from the Ganges Delta of the Indian 
subcontinent. In the nineteenth century, seven distinct pandemic waves of cholera spread 
from Asia to many parts of the world. Six pandemics arose from the Indian subcontinent, 
while the seventh pandemic originated from the island of Sulawesi, Indonesia in 1961 (Parsi, 
2001). In the late 1992, a possible eighth pandemic was reported when a large epidemic 
cholera spread throughout Bangladesh, India, Pakistan, Nepal, China, Thailand and Malaysia 
(Blake, 1994).   
There are more than 150 serogroups of V. cholerae, however only the serogroups O1 
and O139 cause epidemic and pandemic diseases (Sack et al., 2004). The Classical biotype 
of V. cholerae serogroup O1 was responsible for the fifth and sixth pandemics and is 
believed to have been associated with the earlier pandemics as well. The seventh cholera 
pandemic is caused by the El Tor biotype of V. cholerae serogroup O1 and this biotype has 
completely displaced the Classical biotype worldwide, except in Bangladesh where it 
appeared in epidemic proportions in 1982 and now seems to have become extinct again 
(WHO, 2002). The newly emerged serogroup O139 or ‘Bengal’ in the late 1992 has been 
attributed to the eighth cholera pandemic and this serogroup is closely related to the Asian   
V. cholerae O1 El Tor strains associated with the seventh pandemic (Blake, 1994). 
 
1.2 Prevalence of cholera 
Cholera is one of the oldest and best-known diseases in the world, yet it continues to 
cause considerable suffering and needless deaths. In 2006 alone 131,943 cases of cholera 
were reported worldwide with 2272 fatalities (WHO, 2007). However, this number is just the 
tip of the iceberg because poor surveillance and fear of travel and economic sanctions lead to 
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under-reporting of actual cholera cases in certain countries (WHO, 2007). It is estimated that 
in reality, the number of deaths from cholera is probably 100 times more than was officially 
reported (WHO, 2007). In Malaysia, the Ministry of Health reported the incidence rate of 
cholera in 2005 (per 100,000 population) was 1.48 with a 0.01 mortality rate (Ministry of 
Health Malaysia, July 2007).  
 
1.3 Characteristics of V. cholerae 
Vibrio cholerae is a member of the family Vibrionaceae. It is a facultative anaerobe, 
short, curved rod about 1.4 – 2.6 µm, capable of fermentative and respiratory metabolism. It 
is a non-halophilic vibrio, oxidase-positive, reduces nitrate and is highly motile by means of 
a single sheathed polar flagellum. Even though growth of V. cholerae is stimulated by 
addition of 1% sodium chloride, it can grow in nutrient broth without added sodium chloride, 
which is an important distinction from other Vibrio spp. (Kay et al., 1994). It can grow at 16 
– 40°C, with an optimum temperature of 37°C and at pH 7.4 – 9.6 (WHO, 2002).          
The species V. cholerae is divided into more than 150 serogroups based on the 
differences in their somatic (O) antigens. These variations are secondary to differences in the 
oligosaccharide side chains in parts of the cell wall (Parsi, 2001). The serogroup O1 is 
divided into two biotypes, Classical and El Tor, which can be differentiated by tests such as 
hemolysis, hemagglutination, phage typing, polymyxin B sensitivity and Voges-Proskauer 
reaction (table 1.1). Each of the O1 biotype can be further subdivided into two major 
serotypes, Ogawa and Inaba, based on variations in the polysaccharide component of the O 
antigen. Ogawa strains possesses only the A and B antigens while Inaba strains possesses 
only the A and C antigens. A third and rare serotype, Hikojima possesses all three A, B and 
C antigens (Kay et al., 1994).   
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The new serogroup O139 Bengal was thought to have evolved as a result of 
horizontal gene transfer between O1 and non-O1 strains. The O139 strain does not produce 
O1 lipopolysaccharide and lacks some of the genetic material necessary for production of the 
O1 antigen. It has potential for capsule expression and an increased capacity for spread and 
proliferation within the environment (Morris and Cholera Laboratory Task Force, 1994).    
Strains of V. cholerae identified by biochemical tests but do not agglutinate with O1 
and O139 antisera are referred to as non-O1, non-O139 V. cholerae. The non-O1, non-O139 
strains can produce enterotoxins that are similar to cholera toxin (Morris, 1994). Although 
this strain is not involved in cholera epidemics, it can be pathogenic and is frequently 
associated with small sporadic outbreaks of diarrheal disease caused by the consumption of 
contaminated shellfish and from a variety of extraintestinal infections (Morris, 1994).         
Besides the somatic (O) antigen, all V. cholerae possess common heat-labile flagella 
(H) antigen, and this property may be used to distinguish V. cholerae from all other vibrios 
(Kay et al., 1994). Table 1.2 summarizes the different V. cholerae serogroups and their 
antigenic determinants. 
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Table 1.1: Tests for differentiation of Classical and El Tor biotypes of V. cholerae 
serogroup O1  
 
Test / Reaction 
Biotype 
Classical El Tor 
Hemolysis of sheep erythrocytes − + 
Hemagglutination with fowl erythrocytes − + 
Susceptibility to bacteriophage: 
i)  classical phage (group IV) 
ii) El Tor phage (group V) 
 
+ 
− 
 
− 
+ 
Sensitivity to Polymyxin B (50 U) + − 
Produces acetoin in Voges Proskauer                     
test (modified with 1% NaCl) − + 
 
 
 
Table 1.2: V. cholerae serogroups and their antigenic determinants 
 
Typing  
systems Epidemic associated 
Non-epidemic 
associated 
Serogroup O1 O139 Non-O1 
Biotypes Classical El Tor None _ 
Serotypes 
Ogawa 
Inaba 
Hikojima 
None None 
O1 Antigens 
Ogawa – A and B 
Inaba – A and C 
Hikojima – A, B and C 
Does not have      
O1 somatic         
antigen 
Does not have        
O1 somatic           
antigen 
Toxin 
production 
Produces                
cholera toxin 
Produces  
cholera toxin 
Usually does not 
produce cholera 
toxin, sometimes 
produce other toxins 
Polysaccharide 
capsule None Yes None 
 
Adapted from Kay, B., Bopp, C. & Wells, J. (1994) In Vibrio cholerae and Cholera: Molecular to 
global perspectives (Eds, Wachsmuth, I., Blake, P. and Olsvik, O.) American Society for 
Microbiology, Washington DC (table 1, pp. 4) 
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1.4 Ecology of V. cholerae 
Until the late 1970s and early 1980s, it was believed that V. cholerae was highly 
host-dependant and incapable of surviving longer than a few hours or days outside the 
human intestine. However, studies have shown that V. cholerae is a normal inhabitant of 
brackish water and estuarine systems (Colwell and Huq, 1994a). V. cholerae non-O1, non-
O139 strains are frequently isolated from aquatic ecosystems while O1 and O139 strains are 
less frequently isolated. Outside of the host and in the aquatic environment, V. cholerae can 
be found as free swimming cells, attached to aquatic plants, filamentous green algae, 
copepods, crustaceans, insects and egg masses of chronomids. Environmental persistence of 
V. cholerae within natural aquatic habitats during periods between epidemics is facilitated by 
biofilm formation and entry into a viable but non-culturable (VBNC) state (Colwell and 
Huq, 1994b).  
 
1.5 Viable but non-culturable (VBNC) state 
V. cholerae O1 and non-O1, non-O139 strains can enter into a VBNC state in 
response to nutrient deprivation, elevated salinity and reduced temperatures. In this dormant 
state, the V. cholerae cells are reduced in size, become ovoid and do not grow at all on 
standard laboratory media used to isolate V. cholerae. However, Colwell et al. (1994b) found 
that when the VBNC cells of V. cholerae were inoculated into rabbit ileal loops or ingested 
by human volunteers, it caused large accumulation of fluid in the rabbit ileal loops or 
diarrhea in the human volunteers. This may explain the reason attempts to culture and isolate 
V. cholerae from water sources between epidemics often fail. Since V. cholerae in the 
VBNC state in environmental samples may not grow on conventional bacteriologic media, it 
may go undetected unless other detection methods such as immunologic, molecular or direct 
microscopy are employed. Huq et al. (1990) showed that V. cholerae O1 could be detected 
by direct immunofluorescence microscopy throughout the year in their water reservoirs even 
when culturing could not isolate the organism itself. Rapid detection kits for V. cholerae that 
do not require culture called CholeraScreen (a coagglutination test), Cholera DFA (direct 
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fluorescent monoclonal antibody staining kit) and Cholera SMART (a colorimetric 
immunoassay) have been developed and these were also able to detect VBNC cells of         
V. cholerae (Colwell and Huq, 1994b). 
   
1.6 Epidemiology of cholera 
Cholera is the classic water-borne disease and an epidemiological study by John 
Snow in 1849 showed the association of the disease with contaminated drinking water (Parsi, 
2001). Poor sewerage and sanitation practices that resulted in contamination of water 
supplies used for drinking and food preparation are often the causes of cholera epidemics 
(Mintz et al., 1994). This mode of transmission is more common in less developed countries 
under conditions of famine, war and natural disaster. Cholera transmission has also been 
linked to drinking water from shallow wells, rivers, bottled water and ice (Parsi, 2001).  
Food is another vehicle for transmission. Seafood, particularly raw or undercooked 
shellfish harvested from sewage-contaminated seabeds, meat, cooked grains, fruit and 
vegetables irrigated with raw sewerage have been implicated in cholera outbreaks (Parsi, 
2001, Mintz et al., 1994).  
 
1.7 Pathophysiology of cholera 
Upon ingestion, V. cholerae cells colonize the small intestines, particularly the 
duodenum and jejunum because the alkaline pH, nutrients and bile salts provide a suitable 
environment. They adhere to the microvilli with the help of a long filamentous fimbriae 
called toxin-coregulated pili (Tcp pili), hemagglutinins, mucinase and neuraminidase. Their 
motility also enables them to penetrate the mucus layer. They penetrate the host cells by 
elaborating a potent enterotoxin, called cholera toxin (CT), a 84 kDa protein consisting of 2 
regions, which are the A region and B region (Sack et al., 2004). 
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The B region (56 kDa) binds the glycolipid, GM1 ganglioside on the host intestinal 
epithelial cell membrane, enabling the A region (28 kDa) to penetrate the cell. The A region 
will enzymatically transfer ADP-ribose from NAD to a GTP-binding regulatory protein 
associated with membrane-bound adenylate cyclase enzyme. The ADP-ribosylation reaction 
activates adenylate cyclase, which leads to an increase of intracellular cAMP levels. This is 
followed by the secretion of H2O, Na+, K+, Cl- and HCO3- into the lumen (Kaper et al., 1994). 
The patient may lose several litres of protein-free fluid and associated electrolytes, 
bicarbonates and ions within hours. The watery diarrhea (rice-water stool) is speckled with 
flakes of mucus, epithelial cells and contains large number of vibrios. Excessive loss of fluid 
may lead to dehydration, uremia, metabolic acidosis, hypovolemic shock and subsequently, 
death in untreated cases (Sack et al., 2004, Parsi, 2001). The severity of a cholera infection 
depends on many factors, and it is increased with the absence of a local intestinal immunity, 
a high infectious dose (>108 bacteria), low gastric acid production and possession of blood 
group O (Sack et al., 2004, Parsi, 2001).    
 
1.8 Clinical manifestations of cholera 
Most individuals infected with V. cholerae have no symptoms or only mild diarrhea, 
indistinguishable from other mild diarrheal diseases. Only a minority will develop cholera, a 
disease characterized by the sudden onset of vomiting and profuse watery diarrhea, 
following an incubation period of 6 to 48 hours. The most distinctive feature of cholera is the 
painless purging of voluminous stools resembling rice-water and having a fishy odour. In 
adults with severe cholera, the volume of watery stool may exceed 1 L/hour, leading to 
severe dehydration, hypovolemic shock, metabolic acidosis and renal failure. This condition 
may lead to death within a few hours of onset if rapid treatment is not given (Bennish, 1994, 
Parsi, 2001).  
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1.9 Treatment of cholera 
Without proper treatment the case-fatality for severe cholera is about 50% (Sack et 
al., 2004). Treatment is very simple and effective based on fluid replacement. Oral 
rehydration solution (ORS) should be given for mild cases of diarrhea, while intravenous 
fluid replacement using lactated Ringer’s solution should be given for more severe cases 
(Parsi, 2001). The use of antibiotics shortens the duration and severity of the illness. In most 
cases, tetracycline and doxycycline is the antibiotic of choice. In cases of tetracycline 
resistance, erythromycin, cotrimoxazole, ciprofloxacine, azithromycin and trimethoprim-
sulfamethoxazole may be used (Parsi, 2001).          
 
1.10 Prevention of cholera 
Transmission of V. cholerae through contaminated food and water can be prevented 
by minimizing contamination and reducing survival and growth of the organism (Sack et al., 
2004). The level of contamination can be minimized by practicing personal and domestic 
hygiene such as hand washing with soap before food handling and safe sewage disposal. 
Survival of the organism may be diminished by boiling or disinfecting drinking water and 
proper cooking and refrigeration of food. Prophylactic prevention of cholera can be achieved 
through the use of vaccines. Three oral vaccines (two inactivated and one live attenuated) are 
currently available (Sack et al., 2004). These vaccines have been licensed in some countries 
and are mainly used by travellers. However, these vaccines are for V. cholerae serogroup O1 
and do not give cross-protection against other serogroups such as O139 or non-O1, non-
O139. Although a number of vaccine candidates for V. cholerae serogroup O139 are under 
development (Ravichandran et al., 2006), they are not commercially available. Prevention of 
cholera using vaccines may be beneficial as a public health intervention if they are cost-
effective, give long lasting protection and easy to administer.     
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1.11 Diagnosis of cholera 
1.11.1 Conventional laboratory methods 
Due to the clinical and epidemiological severity of cholera, rapid diagnosis of V. 
cholerae in clinical samples, water and food is very critical so that appropriate monitoring 
and effective preventive measures can be undertaken to prevent a cholera outbreak. The 
conventional laboratory methods employed are culturing, microscopy and biochemical 
testing.  
Faecal specimens should be collected as early as possible in the illness, as the 
number of V. cholerae begins to decline soon after onset of symptoms, and before initiation 
of antibiotic therapy (Kay et al., 1994). Faecal specimens or rectal swabs should be collected 
from patients into a sterile bottle containing transport medium such as alkaline peptone water 
(APW). APW is also the standard medium for enrichment of V. cholerae as its high pH 
condition preferentially supports the growth of vibrios while inhibiting other organisms and 
it can be used to recover low levels of vibrios in faecal specimens (Kay et al., 1994).  
If specimen is collected on the first day of illness, the vibrios are likely to be present 
in large numbers (107-109 CFU/ml), hence it is possible to make a provisional diagnosis by 
direct microscopy examination of a film of faeces using dark-field or phase-contrast 
microscopy (Kay et al., 1994). Vibrios are highly motile and can be seen darting about 
rapidly. When specific antiserum is added to the film, the vibrios are immobilized.       
For culture, fresh faecal specimens or APW-enriched specimens are plated onto 
thiosulfate-citrate-bile salts-sucrose (TCBS) agar, a highly differential and selective medium 
for V. cholerae. Its selective ingredients suppress the growth of most of the interfering 
organisms such as coliforms, psedomonads, aeromonads and other Gram-positive bacteria 
(WHO, 2002). The sucrose-fermenting V. cholerae grow on TCBS as large, slightly 
flattened, yellow, smooth colonies with a diameter of 2-4 mm.  
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Identification of O1 or O139 serogroups is performed using slide agglutination test 
with antiserum raised against V. cholerae O1 or O139. Agglutination in polyvalent O1 
antiserum provides presumptive identification of serogroup O1, which must then be 
confirmed by agglutination with monovalent Ogawa and Inaba antisera. Identification of 
serogroup O139 should be performed with specific O139 antiserum (Kay et al., 1994).         
A series of biochemical tests may be used for further identification in addition to 
serological identification. A crucial biochemical test for distinguishing V. cholerae from 
other members of Enterobacteriaceae is the oxidase test. V. cholerae is oxidase-positive 
while all Enterobacteriaceae are oxidase-negative. Other important traits that may be used to 
distinguish V. cholerae include fermentation of glucose with acid production (without gas), 
maltose, mannitol, sucrose and trehalose. In a string test, a loopful of V. cholerae suspended 
in a drop of 0.5% aqueous deoxycholate gives a mucoid “string” when drawn. Inoculation of 
V. cholerae into Kligler iron agar (KIA) or triple sugar iron agar (TSI) produces an alkaline 
slant (K) over acid (A) butt, with no gas or H2S (Kay et al., 1994).    
Conventional culture methods are time-consuming and labour-intensive. It takes at 
least 2 days to obtain results and may lack sensitivity, especially for poorly handled samples 
or clinical samples of patients previously treated with antibiotics as the number of viable and 
culturable organisms may be diminished. Detection may also be difficult if the number of 
viable organism is low, as in some environmental samples where V. cholerae can exist in a 
metabolic state that is non-culturable, but still remain viable and capable of causing disease 
(Colwell and Huq, 1994b). 
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1.11.2    Alternative methods of cholera diagnosis  
1.11.2.1   Immunological-based tests for cholera 
As an alternative to conventional culture methods, several rapid immunological-
based tests have been developed. The earlier studies employed antibodies against V. cholerae 
O1 antigen in enzyme-linked immunosorbent assay (ELISA) format (Martinez-Govea et al., 
2001, Osek et al., 1992, Bhadra et al., 1991, Gustafsson, 1984, Cooper et al., 1983), bead-
ELISA format (Ramamurthy et al., 1996, Ramamurthy et al., 1992, Uesaka et al., 1992, 
Cooper et al., 1983), immunofluorescence microscopy (Goel et al., 2005, Hasan et al., 
1994a, Huq et al., 1990), coagglutination test (Goel et al., 2005, Hasan et al., 1995, Colwell 
et al., 1992, Rahman et al., 1989, Rahman et al., 1987) and colloidal gold-based colorimetric 
immunoassay (Hasan et al., 1994b). Immunoassays for V. cholerae O139 have also been 
developed using coagglutination test (Qadri et al., 1994), immunofluorescence microscopy 
(Hasan et al., 1995), colloidal gold-based colorimetric test (Qadri et al., 1995) and dot-blot 
ELISA (Chaicumpa et al., 1998).  
More recently, antibody-based biosensors, called immunosensors, have been 
described. Jyoung et al. (2006) immobilized monoclonal antibodies against V. cholerae O1 
on a self-assembled monolayer (SAM), whereby binding of O1 antigen to the antibody can 
be detected using surface plasmon resonance (SPR) spectroscopy. Rao et al. (2006) utilized 
an indirect ELISA method in developing an amperometric immunosensor for detection of V. 
cholerae O1 on disposable screen-printed electrodes.   
Most of the immunological assays offer the advantages of speed, simpler reagents 
and equipments, better sensitivity and specificity over culture methods.  Several tests such as 
CholeraScreen, Cholera DFA and Cholera SMART have been reported to be able to detect 
VBNC cells from faecal specimens (Colwell and Huq, 1994b). However, only a few tests are 
commercially available, namely SMARTTM and MedicosTM Cholera Dipstick to detect the 
O1 serogroup but these tests are quite expensive and well beyond the reach of medical 
providers in areas at risk of cholera (Kalluri et al., 2006).   
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1.11.2.2   Molecular-based tests for cholera 
Recently, there has been a move to adopt molecular-based methods as a gold 
standard to replace the traditional culture methods. The use of molecular techniques that rely 
on nucleic acid amplification, such as polymerase chain reaction (PCR), ligase chain reaction 
(LCR), transcription-mediated amplification (TMA), strand displacement amplification 
(SDA) and nucleic acid sequence-based amplification (NASBA) have greatly improved the 
speed, sensitivity and specificity of diagnostic tests. This, in turn, would facilitate early and 
informed decision-making related to patient management, infection control, treatment and 
prevention.  
 PCR assays have been developed to detect the cholera enterotoxin operon, since 
most of the cholera pandemic and epidemics were associated with enterotoxin producing      
V. cholerae (Koch et al., 1993, Fields et al., 1992, Shirai et al., 1991). Subsequently, a 
multiplex PCR assay was developed to detect toxigenic strains of V. cholerae based on the 
cholera toxin gene and to identify its biotype based on the hyl gene (Shangkuan et al., 1995).  
As the new cholera pandemic involving the serogroup O139 began to emerge, 
various PCR tests were developed to detect this new serogroup O139 alone (Albert et al., 
1997), or both the serogroups O139 and O1 (Gubala, 2006, Lipp et al., 2003, Lyon, 2001, 
Singh et al., 2001, Albert et al., 1997, Rivera et al., 1995). Besides detecting the serogroups 
O1 and O139, Nandi et al. (2000) and Di Pinto et al. (2005) have developed PCR assays 
based on non-virulence genes such as the ompW and collagenase gene, respectively, which 
were able to detect certain non-toxigenic V. cholerae strains of the serogroups non-O1, non-
O139. This serogroup is often found in environmental samples and causes sporadic and 
localized diarrheal outbreaks (Vital-Brazil et al., 2002, Kaper et al., 1994).   
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1.11.2.2.1  Characteristics and advantages of molecular-based tests over conventional  
methods 
The advantage of PCR over conventional culturing in detecting viable but non-
culturable (VBNC) cells of V. cholerae was proven in a study by Chaiyanan et al. (2001). 
Conservation of cholera toxin-associated genes like ctxA, tcpA, toxR and zot in chromosomal 
DNA of VBNC cells was demonstrated using PCR. It was shown that VBNC cells retained 
their viability, along with their genes and chromosomal integrity up to one year.  
PCR assays are rapid, highly sensitive, specific and can detect more than one gene at 
the same time. Although the advantages of PCR-based test over conventional culture method 
are numerous, there are certain limitations to the test. PCR requires the use of a thermal 
cycler and even with recent advances in this field, the cost and size of a thermal cycler limit 
its use in laboratories with limited resources (Lai et al., 2006). In addition, PCR reagents 
must be transported and stored at –20°C and maintaining a constant cold chain may not be 
possible when transporting to far or remote places.  
These are important considerations in developing a diagnostic test for cholera, as 
cholera is a disease that affects most of the poor under-developed countries, or countries 
ravaged by war or natural disasters. Hence, there are not many PCR-based tests for cholera 
in the market, while those that are available commercially are immunochromatographic-
based assays, which can be quite expensive and still require refrigeration for long term 
storage (Kalluri et al., 2006). 
PCR can amplify DNA from both live (viable) and dead (non-viable) cells, since 
DNA can remain intact and undegraded long after cell death. Thus, PCR-based tests cannot 
differentiate viable from non-viable cells. Since cholera is transmitted mainly by 
contaminated food and water, detection of viable cells from these samples is desirable during 
an epidemic to identify the source of infection and implement control measures. It is 
important that positive test results are associated with live cells and not the remains of dead 
cell. Identification of live cells would also help clinicians in monitoring the effectiveness of 
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antimicrobial treatments in patients (Bej et al., 1996). Detection of viable microorganisms 
after sterilization procedures is also important in the medical and food industry to ensure 
effectiveness of the process.  
RNA has been suggested as a suitable indicator of cell viability as it rapidly degrades 
after cell death (Sheridan et al., 1999, Sheridan et al., 1998). Detection of RNA is possible 
through reverse-transcription PCR (RT-PCR), a modification of the PCR process, which first 
converts the RNA to cDNA, and subsequently the cDNA is amplified by PCR. RT-PCR is a 
multiple step process and even small amounts of DNA in the RNA sample might get 
amplified, thus giving a false-positive result. Therefore, all RNA samples need to be treated 
with DNase enzyme prior to RT-PCR.    
 
1.11.2.3 Nucleic acid sequence-based amplification (NASBA) 
Besides RT-PCR, another RNA-based amplification technique is nucleic acid 
sequence-based amplification (NASBA). NASBA is an isothermal amplification assay that 
specifically amplifies RNA. The reaction occurs at a relatively low temperature of 41°C that 
does not promote the denaturation of double-stranded DNA, hence DNA is not amplified 
(Deiman et al., 2002). Furthermore, it can be performed using a simple water bath or heating 
block. NASBA produces more amplicons in a shorter time than PCR, requiring only 60 – 90 
minutes of assay time, compared to 2 – 3 hours for RT-PCR. Amplification of approximately 
106 to 109-fold is obtained within 90 minutes (Compton, 1991).  
The single-stranded RNA amplicons can be detected using various methods, such as  
agarose gel electrophoresis (Jean et al., 2004, Jean et al., 2002b), molecular beacon-based 
real-time amplification technique (Loens et al., 2008, Churruca et al., 2007, Deiman et al., 
2007, Fykse et al., 2007, Nadal et al., 2007) and probe hybridisation techniques, such as 
Northern blotting (Jean et al., 2004, Jean et al., 2002b), ELISA (Lau et al., 2008, Jean et al., 
2002a, Jean et al., 2002b), electrochemiluminescence (ECL) (Lau et al., 2008, Collins et al., 
2003, Hibbitts et al., 2003), enzyme-linked gel assay (ELGA) (Lau et al., 2008, Hibbitts et 
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al., 2003) and biosensors (Baeumner et al., 2004a, Baeumner et al., 2004b, Zaytseva et al., 
2004). These features make NASBA a suitable molecular-based test for cholera. Figure 1.1 
shows an overview of the NASBA reaction.   
NASBA was first reviewed in 1991 by Compton (1991), who described the salient 
features of the technology and its applications. Kievits et al. (1991) was among the earliest to 
describe the use of NASBA for the diagnosis of HIV-1 infection. Since NASBA is an RNA 
amplification technology, it is suitable for detection of RNA viruses, such as norovirus (Kou 
et al., 2006, Patterson et al., 2006, Rutjes et al., 2006), enterovirus (Casper et al., 2005, 
Landry et al., 2005), hepatitis A virus (Abd el-Galil et al., 2005) and cytomegalovirus 
(Bergallo et al., 2006, Revello et al., 2003). 
NASBA provided researchers with a way of detecting viable microorganisms in 
clinical samples, food and environmental samples, as presence of intact RNA is a valuable 
indicator of viability. Detection of viable microorganisms is important for screening of 
contaminated food (Cook, 2003, Gore et al., 2003) and environmental samples (Fykse et al., 
2007, Rutjes et al., 2006, Baeumner et al., 2003); monitoring the clinical course of a disease 
(Yoo et al., 2005); and assessing the efficacy of antimicrobials and other treatments (de 
Vries et al., 2006).  
A real-time NASBA assay for V. cholerae was developed by Fykse et al. (2007) 
targeting genes encoding cholera (ctxA), toxin-corregulated pilus (tcpA), ctxA toxin regulator 
(toxR), hemolysin (hlyA) and the 60 kDa chaperonin product (groEL). The assay was able to 
detect V. cholerae from various environmental water samples and has a strong potential for 
detecting toxigenic strains using the tcpA and ctxA markers.       
Besides detection of medically important microorganisms, other clinical applications 
of NASBA include detection of biomarkers and important human genes. NASBA has also 
been used to detect disease-causing microorganisms in the marine, agriculture and livestock 
industries (Lau et al., 2008, Lau et al., 2006, Olmos et al., 2007, Teng et al., 2006). 
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Figure 1.1: Overview of the NASBA reaction  
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1.12 Rationale of the study 
Most of the molecular-based diagnostic tests that have been developed for                
V. cholerae are either PCR or real-time based PCR assays. These assays require constant 
cold chain for transport and storage of the PCR reagents, skilled laboratory technicians and 
sophisticated equipments to perform the tests. Moreover PCR assays detect DNA, which 
may still be present in dead cells; therefore it cannot be used to differentiate between viable 
and non-viable cells. Identification of viable V. cholerae is important especially during a 
cholera epidemic, where detection of viable cells from food and water samples is desirable to 
identify the source of infection and implement control measures. It is also useful for testing 
environmental samples for reservoirs of viable V. cholerae.     
 We have identified a non-virulence gene called lolB (hemM), which codes for an 
outer membrane protein in V. cholerae. The lolB gene sequence has been submitted to the 
Genbank under the accession number AF227752. The lolB gene sequence was found to be 
highly conserved among the different serogroups of V. cholerae. A PCR assay was 
developed that was able to detect O1, O139 and non-O1, non-O139 serogroups of                 
V. cholerae from clinical and environmental samples with 98.5% sensitivity and 100% 
specificity (Lalitha et al., 2008).   
The present study used the lolB gene as a candidate in the development of a cholera 
NASBA-ELISA assay for detection of V. cholerae. The cholera NASBA-ELISA assay with 
biosensor detection would be a suitable detection method for viable V. cholerae as it does 
not require expensive and specialized equipments. The present study also aims to make 
NASBA easy to perform and to eliminate the need for cold storage of NASBA reagents 
through the use of our patent-pending thermostabilization technology (Ravichandran et al., 
2005), which has been successfully applied in thermostabilization PCR assays for typhoid 
and cholera  (Aziah et al., 2007, Ravichandran et al., 2003). To the best of our knowledge, 
this is the first time a thermostabilized cholera NASBA-ELISA assay featuring the use of a 
portable biosensor is described.  
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1.13 Objectives of the study  
 
Phase 1: Development and optimization of a cholera NASBA assay  
1. To design specific primers and probes for cholera NASBA assay 
2. To construct in vitro RNA transcripts as positive control 
3. To develop and optimize a cholera NASBA assay targeting the lolB gene of V. cholerae  
4. To analyze the NASBA reaction and its amplicons 
5. To test the suitability of lolB mRNA as an indicator of cell viability 
 
Phase 2: Development and optimization of ELISA for detection of cholera NASBA 
amplicons (cholera NASBA-ELISA)   
6. To develop and to optimize an ELISA test for detection of NASBA amplicons by 
comparison of two ELISA formats 
7. To evaluate the cholera NASBA-ELISA assay with spiked stool samples  
8. To calculate the diagnostic sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of the clinical evaluation 
 
Phase 3: Development of an electrochemical biosensor detection for cholera NASBA 
ELISA assay         
9. To optimize detection of the NASBA-ELISA signal with an electrochemical biosensor 
10. To compare the biosensor results with spectrophotometric measurements 
 
Phase 4: Optimization of a thermostabilized NASBA mix  
10. To optimize the enzymes and enzyme stabilizer concentrations for thermostabilization of       
the NASBA mix 
11. To determine the stability of the thermostabilized NASBA mix stored at different 
temperatures over a certain period of time 
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1.14 Overview of the study 
 
 
 
Viability assay
Confirmation of NASBA 
amplicons as RNA by 
RNase and DNase-
digestions   
Development and optimization of ELISA for                 
detection of NASBA amplicons (NASBA-ELISA) 
Evaluation of NASBA-ELISA with spiked stool samples  
Optimization of an electrochemical biosensor method          
for detection of ELISA reaction 
Periodic stability evaluation of the 
lyophilized NASBA mix 
Optimization of a thermostabilized formulation for 
lyophilization of the NASBA mix 
Determination of analytical specificity and sensitivity  
Comparison of biosensor and 
spectrophotometry results  
Determination of analytical 
sensitivity and specificity 
Determination of 
analytical sensitivity
Determination of diagnostic sensitivity, specificity,            
PPV, NPV and limit of detection (LOD) 
Development and optimization               
of a NASBA assay targeting the             
lolB gene of Vibrio cholerae 
Detection of NASBA amplicons by           
agarose gel electrophoresis 
Determination of 
analytical sensitivity
Determination of 
analytical specificity  
Analysis of NASBA reaction and amplicons 
Construction of in vitro 
RNA transcripts 
Investigation of DNA as 
template in NASBA  
Confirmation of NASBA 
amplicons by Northern 
blot and dot-blot
PHASE 
2
PHASE 
3 
PHASE 
1 
PHASE 
4 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Bacterial strains 
2.1.1.1 Reference strains 
 Six V. cholerae strains comprising of O1, O139 and non-O1, non-O139 serogroups 
were used as reference strains for optimization and evaluation of the sensitivity of the 
NASBA assay. Six other Vibrio species strains and 29 enteric pathogen strains were used as 
reference strains for evaluating the specificity of the NASBA assay. The V. cholerae, Vibrio 
spp. and 10 enteric pathogen strains were obtained from Prof. Mitsuaki Nishibuchi, Centre 
for Southeast Asia Studies, Kyoto University, Japan as a gift. The remaining 19 enteric 
pathogen strains were obtained from the culture collection of the Department of 
Microbiology and Parasitology, Universiti Sains Malaysia, Malaysia. Details of the reference 
strains used in this study are given in table 2.1.  
 
2.1.1.2 Clinical isolates 
 For evaluation of the NASBA assay using spiked stool samples, 110 well-
characterized strains of V. cholerae isolated from clinical samples were obtained from Centre 
for Southeast Asia Studies, Kyoto University, Japan; Communicable Diseases Hospital, 
Thandiarpettai, Chennai, India; Hospital Universiti Sains Malaysia (HUSM) and General 
Hospital Kota Bharu (GHKB), Kota Bharu, Kelantan; National Public Health Laboratory 
(MKAK), Ministry of Health, Sungai Buloh; and Institute for Medical Research (IMR), 
Selangor, Malaysia.  
 In addition, 45 well-characterized strains of other Vibrio species and various enteric 
pathogens isolated from clinical samples were also obtained from Centre for Southeast Asia 
Studies, Kyoto University, Japan; Hospital Universiti Sains Malaysia (HUSM), Kota Bharu, 
Kelantan and Institute of Medical Research (IMR), Selangor, Malaysia.  
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 All 41 reference strains were also included in the evaluation of the NASBA assay 
using spiked stool samples as these were originally isolated from clinical samples. Details of 
the clinical isolates used in the study are given in table 2.2.  
 
2.1.1.3 Growth and maintenance of bacterial strains 
 All bacterial strains were preserved and maintained as glycerol stock in LB broth 
with 15% glycerol and kept at -70°C. For experimental purposes, the bacterial strains were 
revived from glycerol stocks by inoculating a loopful of culture into LB broth and incubated 
overnight at 37°C. For V. cholerae strains, the overnight cultures were then subcultured onto 
TCBS agar while for other enteric bacteria, the overnight cultures were subcultured onto LB 
agar and incubated overnight at 37°C. V. cholerae appeared as yellow, convexed and mucoid 
colonies on TCBS agar. A single colony was picked with a sterile wire loop, streaked onto 
LB agar and incubated overnight at 37°C again. These cultures were used to perform the 
NASBA assay. 
 
2.1.2 Culture Media 
 Culture media were prepared using molecular biology or biotechnology grade 
chemicals. Distilled water was used for preparing media solutions. The appropriate media 
were autoclaved at 121°C, 15 psi for 15 minutes. Sterility check was performed by 
incubating the media at 37°C overnight. Sterile agar media were stored at 4°C while broth 
and other liquid media were stored at room temperature. The list of culture media used in 
this study is given in appendix A.       
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Table 2.1: Details of the reference strains used in this study 
 
Reference 
strains Source Serogroup or species 
No. of 
strains 
 
Vibrio 
cholerae  
(n = 6)  
 
Centre for 
Southeast Asia 
Studies, Kyoto 
University, Japan 
 
 
V. cholerae, O1 Classical 
V. cholerae, O1 El Tor 
V. cholerae, O139 Bengal 
V. cholerae, non-O1, non-O139 
 
 
2 
2 
1 
1 
 
Other  
Vibrio spp. 
(n = 6) 
 
Centre for 
Southeast Asia 
Studies, Kyoto 
University, Japan 
 
V. cincinnatiensis 
V. fluvialis 
V. furnissii 
V. mimicus 
V. parahaemolyticus 
V. vulnificus 
 
 
1 
1 
1 
1 
1 
1 
 
Enteric 
pathogens 
(n = 29) 
 
Centre for 
Southeast Asia 
Studies, Kyoto 
University, Japan 
 
 
 
 
 
 
Department of 
Microbiology 
and Parasitology, 
Universiti Sains 
Malaysia 
 
 
 
Aeromonas hydrophila 
Escherichia coli 
Pleisiomonas shigelloides 
Salmonella enteritidis 
Salmonella typhi 
Shigella boydii 
Shigella dysenteriae 
Shigella flexneri 
Shigella sonnei 
 
Acinetobacter spp. 
Acinetobacter baumanii 
Bacillus cereus 
Bacillus subtilis 
Burkholderia pseudomallei 
Citrobacter freundii 
Enterobacter cloacae 
Klebsiella spp. 
Klebsiella pneumoniae 
Morganella morganii 
Proteus mirabilis 
Proteus vulgaris 
Providencia stuartii 
Pseudomonas aeruginosa 
Salmonella spp. 
Salmonella para typhi A 
Salmonella para typhi B 
Serratia marsescens 
Yersinia enterocolitica 
 
 
1 
2 
1 
1 
1 
1 
1 
1 
1 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
  TOTAL 41 
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Table 2.2: Details of the clinical isolates used in this study 
 
Clinical 
isolates Source Serogroup or species 
No. of 
isolates 
 
Vibrio 
cholerae  
(n = 116) 
 
Hospital Universiti Sains 
Malaysia (HUSM), 
Kelantan, Malaysia 
 
General Hospital, Kota 
Bharu (GHKB), 
Kelantan, Malaysia 
 
National Public Health 
Laboratory, Ministry of 
Health, Sungai Buloh, 
Selangor, Malaysia 
 
Institute for Medical 
Research (IMR), 
Selangor, Malaysia 
 
Communicable Diseases 
Hospital, Thandiarpettai, 
Chennai, India 
 
Centre for Southeast 
Asia Studies, Kyoto 
University, Japan 
 
V. cholerae, O1  
 
 
 
V. cholerae, O1  
 
 
 
V. cholerae, O1  
 
 
 
 
V. cholerae, O1  
V. cholerae, O139 Bengal 
V. cholerae, non-O1, non-O139 
 
V. cholerae, O139 Bengal 
 
 
 
V. cholerae, O1  
V. cholerae, O139 Bengal 
V. cholerae, non-O1, non-O139 
 
8 
 
 
 
17 
 
 
 
6 
 
 
 
 
55 
1 
3 
 
9 
 
 
 
14 
2 
1 
 
Other  
Vibrio 
spp. 
(n =12) 
 
Centre for Southeast 
Asia Studies, Kyoto 
University, Japan  
 
 
 
 
Institute for Medical 
Research (IMR), 
Selangor, Malaysia 
 
V. cincinnatiensis 
V. fluvialis 
V. furnissii 
V. mimicus 
V. parahaemolyticus 
V. vulnificus 
 
V. vulnificus 
 
 
 
1 
3 
2 
2 
1 
2 
 
1 
 
 
Enteric 
pathogens 
(n = 68) 
 
Centre for Southeast 
Asia Studies, Kyoto 
University, Japan 
 
 
Aeromonas hydrophila 
Escherichia coli 
Pleisiomonas shigelloides 
Salmonella enteritidis 
Salmonella typhi 
Shigella boydii 
Shigella dysenteriae 
Shigella flexneri 
Shigella sonnei 
 
1 
4 
1 
1 
1 
1 
1 
1 
1 
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Table 2.2 (continued) 
 
 
Clinical 
isolates Source Serogroup or species 
No. of 
isolates 
 
Enteric 
pathogens 
(n = 68) 
 
Department of 
Microbiology and 
Parasitology, Universiti 
Sains Malaysia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institute for Medical 
Research (IMR), 
Selangor, Malaysia 
 
 
 
 
 
Acinetobacter spp. 
Acinetobacter baumannii 
Bacillus cereus 
Bacillus subtilis 
Burkholderia pseudomallei 
Citrobacter freundii 
Enterobacter cloacae 
Escherichia coli 
Klebsiella spp. 
Klebsiella pneumoniae 
Morganella morganii 
Proteus vulgaris 
Pseudomonas aeruginosa 
Salmonella enteritidis 
Salmonella typhi 
Serratia marsescens 
Shigella boydii 
Staphylococcus aureus 
Streptococcus group G 
 
Aeromonas hydrophila 
Acenitobacter baumanii 
Bacillus cereus 
Burkholderia pseudomallei 
Enterococus faecalis 
Klebsiella spp. 
Klebsiella pneumoniae 
Proteus mirabilis 
Providencia stuartii  
Salmonella spp. 
Salmonella enteritidis 
Salmonella para typhi A 
Salmonella para typhi B 
Salmonella typhi 
Shigella boydii 
Shigella dysenteriae 
Shigella flexneri 
Shigella sonnei 
Staphylococcus aureus 
Yersinia enterocolitica 
 
 
1 
1 
1 
1 
1 
2 
1 
1 
1 
1 
1 
1 
2 
1 
1 
1 
1 
1 
1 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
4 
1 
5 
3 
4 
2 
2 
1 
2 
1 
1 
  TOTAL 196 
 
 
 
